Testing effectiveness (Phase 2)Study completedNCT02150213
What this trial is testing
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Who this might be right for
Adrenocortical AdenomaEndometrial Stromal Sarcomas
Novartis Pharmaceuticals 59